Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Pande Made S. Dharma Pathni
Medical Department, PT Kalbe Farma Tbk., Jakarta, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

 1 
Terapi Diabetes dengan SGLT-2 Inhibitor Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 46, No 6 (2019): Diabetes Mellitus
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.471

Abstract

SGLT-2 adalah transporter glukosa yang terletak di tubulus proksimal ginjal dan bertanggung jawab terhadap 90% reabsorpsi glukosa. Inhibisi terhadap transporter ini akan berdampak pada penurunan kadar glukosa darah dengan cara meningkatkan ekskresi glukosa melalui ginjal, namun kerjanya tergantung kadar glukosa.SGLT-2 is a glucose transporter located at renal proximal tubules and is responsible for 90% glucose reabsorption. Inhibition to this transporter resulted in a decrease of blood glucose through increased renal glucose excretion, but the action is dependent on blood glucose level.
Terapi Diabetes dengan GLP-1 Receptor Agonist Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 45, No 4 (2018): Cedera Kepala
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v45i4.668

Abstract

GLP-1 menjadi target terapi DM tipe 2. Analog GLP-1 memiliki aktivitas serupa GLP-1 endogen, namun dengan kelebihan resisten terhadap deaktivasi enzim DPP-4, menghasilkan aktivitas yang lebih panjang. Manfaat lain obat golongan ini adalah menurunkan kadar hormon glukagon, memperlambat pengosongan lambung, dan menginduksi rasa kenyangGLP-1 become a therapeutic target of type 2 DM. Analogue of GLP-1 has the activity that mimics endogenous GLP-1, with advantages to be resistant to DPP-4 enzyme deactivation, resulting in longer activity. Other activities of this class is to lower glucagon hormone level, slow gastric emptying and induce satiety.  
Terapi Diabetes dengan SGLT-2 Inhibitor Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 46 No 6 (2019): Endokrinologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.442

Abstract

SGLT-2 adalah transporter glukosa yang terletak di tubulus proksimal ginjal dan bertanggung jawab terhadap 90% reabsorpsi glukosa. Inhibisi terhadap transporter ini akan berdampak pada penurunan kadar glukosa darah dengan cara meningkatkan ekskresi glukosa melalui ginjal, namun kerjanya tergantung kadar glukosa. SGLT-2 is a glucose transporter located at renal proximal tubules and responsible for 90% glucose reabsorption. Inhibition to this transporter resulted in a decrease of blood glucose through increased renal glucose excretion, but the action is dependent on blood glucose level.
Tren Terapi Diabetes dengan GLP-1 Receptor Agonist Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 45 No 4 (2018): Neurologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v45i4.803

Abstract

GLP-1 menjadi target terapi DM tipe 2. Analog GLP-1 memiliki aktivitas serupa GLP-1 endogen, namun dengan kelebihan resisten terhadap deaktivasi enzim DPP-4, menghasilkan aktivitas yang lebih panjang. Manfaat lain obat golongan ini adalah menurunkan kadar hormon glukagon, memperlambat pengosongan lambung, dan menginduksi rasa kenyang.   GLP-1 becomes a therapeutic target of type 2 DM. Analogue of GLP-1 has the activity that mimics endogenous GLP-1, with advantages to be resistant to DPP-4 enzyme deactivation, resulting in longer activity. Other activities of this class are to lower glucagon hormone level, slow gastric emptying and induce satiety.
Terapi Diabetes dengan SGLT-2 Inhibitor Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 46 No 6 (2019): Endokrinologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.442

Abstract

SGLT-2 adalah transporter glukosa yang terletak di tubulus proksimal ginjal dan bertanggung jawab terhadap 90% reabsorpsi glukosa. Inhibisi terhadap transporter ini akan berdampak pada penurunan kadar glukosa darah dengan cara meningkatkan ekskresi glukosa melalui ginjal, namun kerjanya tergantung kadar glukosa. SGLT-2 is a glucose transporter located at renal proximal tubules and responsible for 90% glucose reabsorption. Inhibition to this transporter resulted in a decrease of blood glucose through increased renal glucose excretion, but the action is dependent on blood glucose level.
Tren Terapi Diabetes dengan GLP-1 Receptor Agonist Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 45 No 4 (2018): Neurologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v45i4.803

Abstract

GLP-1 menjadi target terapi DM tipe 2. Analog GLP-1 memiliki aktivitas serupa GLP-1 endogen, namun dengan kelebihan resisten terhadap deaktivasi enzim DPP-4, menghasilkan aktivitas yang lebih panjang. Manfaat lain obat golongan ini adalah menurunkan kadar hormon glukagon, memperlambat pengosongan lambung, dan menginduksi rasa kenyang.   GLP-1 becomes a therapeutic target of type 2 DM. Analogue of GLP-1 has the activity that mimics endogenous GLP-1, with advantages to be resistant to DPP-4 enzyme deactivation, resulting in longer activity. Other activities of this class are to lower glucagon hormone level, slow gastric emptying and induce satiety.
Co-Authors